cyrilzakka/clinical-trials huggingface dataset:
Prevalence of Orthostatic Tremor in Patients With Unsteadiness

Clinical presentation of orthostatic tremor (OT) may be misleading and simply perceived by a postural instability such as in several peripheral neuropathies. In addition, peripheral neuropathies represent the leading cause of pathologies associated with OT. Among patients referred for an electroneuromyogram (ENMG) for peripheral neuropathy and presenting with postural unsteadiness, OT assessment will be systematically performed. Demographic, clinical and polygraphy characteristics of these patients will be analyzed and prevalence of OT in the general population of peripheral neuropathies will be assessed.

Among patients who will be referred for ENMG and exploration of a neuropathy, orthostatic tremor will be investigated systematically.

Main objective and primary endpoint:

* To estimate the prevalence of OT with its 95% confidence interval in the population of patients defined above
* Presence of OT confirmed by surface EMG (polygraphy) in patients with standing instability referred for ENMG.

Secondary objectives and end points

* Determine the demographic, clinical, electrophysiological characteristics of patients with OT; Estimate the prevalence of peripheral neuropathy in patients with OT; Duration of symptoms; Correlation with quantitative neuropathy scores (ISS, MRC, ONLS, R-ODS)
* Age, sex, clinical parameters: symptoms reported by the patient (instability, tremor, weakness, pain, falls), duration, current medications, ISS score, MRC score, ONLS score, R-ODS score) and electrophysiological parameters (mean frequency of OT in Hertz, MUNIX score (number of motor units in the anterior tibialis, calculated by software on the ENMG machine).

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old
* All patients complaining of instability when standing up and referred for an ENMG
* Patient informed and having expressed his non-opposition to participating in the research

Exclusion Criteria:

* Patient's refusal to participate in the study
* Impossibility to stand
* No affiliation to health insurance
* Patients under a legal protection measure or unable to express their will
* Patient under the State Medical Assistance (AME)
* Patient under 18 years old
* Pregnant women, parturients and breast-feeding mothers
Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks

The purpose of this study is to assess the effectiveness, safety, and acceptability of home-administered medical abortion at gestational age of 8 to ≤9 weeks versus \>9 to ≤12 weeks among a cohort of women in Mexico City.

Medical abortion represents an important alternative to surgical methods for termination of early pregnancy. In Mexico City, abortion is legal on request up to 12 weeks of gestation; however, medical abortion is currently only offered up to 10 weeks at Marie Stopes Mexico clinics. The World Health Organization guidelines state that medical abortion drugs may be used to terminate pregnancy up to a gestational age of 24 weeks in clinical settings, with recommended regimens differing by gestational age. However, data are lacking on the safety and effectiveness of home-based medical abortion regimens for pregnancy terminations between \>9 and ≤12 weeks' gestation. Investigators propose a prospective cohort study with women between 8 and ≤9 weeks and \>9 and ≤12 weeks of pregnancy at Marie Stopes Mexico clinics to compare the effectiveness, safety, and acceptability of mifepristone followed by home-based misoprostol use in these two gestational age groups. The information from this study will inform policy and practice guidelines in Mexico City and potentially other locations by providing evidence on the safety, effectiveness, and acceptability of home-use of medical abortion between \>9 and ≤12 weeks of gestation.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 or older
* Intrauterine pregnancy 57- 84 days, assessed using clinical assessment and transvaginal or transabdominal ultrasound by crown-rump length (machines will be calibrated and will use a standardized conversion formula to determine gestational age)
* Eligible for medical abortion according to doctor assessment
* Elected medical abortion over surgical abortion after comprehensive counselling
* Haemoglobin level ≥10 g/dl measured by Hemocue
* Willing and able to sign consent forms
* Able to speak and read Spanish
* Agree to comply with the study procedures and visit schedule
* Access to own telephone and to emergency transportation
* Access to a toilet with privacy
* Reside no more than 30 minutes car journey from the Sta. Mónica Hospital in Polanco or the Marie Stopes Mexico Roma Clinic

Exclusion Criteria:

* History or evidence of disorders that represent a contraindication to the use of mifepristone or misoprostol (chronic adrenal failure, severe asthma uncontrolled by corticosteroid therapy, inherited porphyries, glaucoma, mitral stenosis, hepatic or renal disease)
* History of bleeding disorder or current anticoagulant therapy
* Previous allergic reaction to any drugs in the regimen
* Suspicion of any pathology of pregnancy (e.g. molar, ectopic, non-viable pregnancy)
* Multiple gestation
* Presence of an intrauterine device
Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors added to regular statin therapy on target lesion failure (TLF) and arteriosclerosis progression in patients with chronic total occlusions (CTOs) undergoing successful percutaneous coronary intervention (PCI).

Chronic total occlusions (CTOs) are found in 15-25% of patients with stable angina pectoris. The presence of a CTO indicates unfavorable prognosis, with higher rate of major adverse cardiovascular events. Statins are frequently used after PCI in order to lower LDL cholesterol levels and reduce the chances of coronary artery obstruction recurring. Despite this preventive measure, high risk for restenosis and re-occlusion was observed a significant proportion of patients with CTOs undergoing PCI.

Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors represent a novel class of lipid-lowering drugs leading to rapid, profound, and consistent reductions in LDL-C levels. The effect of PCSK9 inhibitor in patients with CTO, after a recent PCI is not known.

In this study the investigators want to evaluate the effect of the PCSK9 inhibitor on neointimal hyperplasia and target lesion failure (TLF) in patients with CTOs receiving regular statin treatment. A serial of intravascular ultrasound imaging study will be performed to determine the arteriosclerosis progression at 48 weeks.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years of age with written informed consent
* Presence of a CTO in native coronary artery.
* Stable angina or myocardial ischemia in a territory supplied by CTO
* CTO located in segments 1-3 (RCA), 6-7 (LAD), 11-12 (LCx)
* Target artery ≥2.5mm
* Scheduled to undergo percutaneous coronary intervention (PCI)
* LDL-C ≥70 mg/dL (≥1.8 mmol/L) in patients who have been on any stable statin regimen for ≥ 4 weeks prior to enrollment; or LDL-C ≥125 mg/dL (≥3.2 mmol/L) in patients who are statin-naïve or have not been receiving stable statin regimen for ≥ 4 weeks prior to enrollment

Exclusion Criteria:

* Acute myocardial infarction within 1 month
* Known severe chronic kidney disease (estimated Glomerular Filtration Rate \[eGFR\] \<60 mL/min/1.73m2 or serum creatinine level \>2.5 mg/dL);
* History of allergy to iodine contrast agents
* Allergy to PCSK9 inhibitors or any other ingredients contained in study drug
* Pregnancy or breastfeeding
* Persistent or permanent atrial fibrillation
* Patients with history of coronary artery bypass graft
* Inability or unwilling to provide informed consent
* Malignant neoplasms or Major illness with life expectancy \<1 year
* Planned coronary revascularization or major non-cardiac surgery 12 months after intervention
* Patients previously treated with PCSK9 inhibitors.
Coronary Hybrid Revascularisation Study

The purpose of the registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.

Based on existing literature we expect the results of coronary artery bypass grafting of the anterior descendent coronary artery (LAD), segment 1 and 2, using the so-called mammary artery graft, to be superior to stent treatment of the same artery.

At the same time a catheter based intervention using balloon, bare metal stents (BMS) or drug eluting stents (DES) seems to be a better treatment that a saphenous vein graft for other coronary arteries than the LAD. I.e. the right coronary artery (RCA) and the left circumflex coronary artery (CX).

Therefore, we expect a combination of the mentioned surgical and catheter based techniques to be a better treatment than bypass operation or catheter based intervention alone.

A total of 150 consecutive patients will be included in the study. The patients will have a coronary artery narrowing located to the LAD, which can be treated with a mammary graft, and a stenosis located to other coronary arteries (RCA and CX), which can be treated by balloon or stent.

The patients included in the study will be recruited from patients who are referred to the Department of Cardiology/Department of Thoracic Surgery, Aarhus University Hospital, Skejby for treatment of significant coronary artery disease. We will not announce for patients, and the patients will not receive a honorarium for participation.

The first 100 patients will be treated i two seances; operation and stent treatment with few days interval. The last 50 patients will be treated in a hybrid operation room with operation and stent treatment in the same seance.

Eligibility Criteria:
Inclusion Criteria:

* Stable, unstable angina pectoris and ACS.
* Significant stenosis of LAD, segment 1 or 2 and of other coronary arteries.
* The patient can be treated with a mammary graft to LAD and by balloon or stent of other lesions.
* Signed informed consent must be available.

Exclusion Criteria:

* Earlier cardiac surgery
* Treatment with coronary stent within one year.
* ST-elevation infarction within 24 hours.
* Coronary artery lesions located to LAD, segment 1 or 2, which cannot be treated by coronary bypass operation.
* Stenosis of diagonal branches, CX artery and the right coronary artery, which cannot be treated by PCI.
* Expected survival \<1 year following successful treatment.
* Allergy to aspirin, clopidogrel, ticlopidine and/or prasugrel.
* Allergy to sirolimus, everolimus, zotarolimus og biolimus

For the patients treated with coronary hybrid intervention in the same seance further exclusion criteria:

Known disorder of the bloods ability to coagulate (such as renal failure (dialysis or renal creatinine clearance \< 50ml/min), congenital coagulopathy, needs for anticoagulant treatment before surgery) Previous gastrointestinal bleeding or previous cerebral
Utility of ChatGPT in Pre-vasectomy Counselling in an Office-based Setting

The investigators wish to perform a pilot study at the Manitoba Men's Health Clinic to assess if pre-vasectomy counseling with ChatGPT can safely streamline the consultation process by reducing visit times, while increasing patient satisfaction with the consultation process.

The release of ChatGPT, a natural language AI chat bot, has recently captured the attention of the general public and medical professionals world-wide. ChatGPT is a conversational AI language model designed by OpenAI that utilizes deep learning techniques to generate human like responses to questions. There has been increasing interest among the medical community on developing new ways to harness this technology to aid medical professionals. New applications have included writing scientific manuscripts, drafting correspondents, as well as testing its ability on standardized medical licensing examinations. ChatGPT was able to perform at or near passing threshold on the United States Medical Licensing Exam (USMLE). Despite ChatGPT demonstrating good medical knowledge, it is still unclear if this translates to real world clinical practice.

Physician burnout is becoming an increasing problem. Per a recent Canadian Urologic Association (CUA) census, burnout was identified in 39% of urologists, with high number of patient visits/week to be cited as a predictor predictive of burnout. That begs the question, can ChatGPT be used for patient counseling and to improve patient flow in one's practice? ChatGPT has been shown to provide effective and safe responses to medical questions and even "curbside" consultations. However its ability to counsel patients in real time has not yet been studied.

As such, the investigators wish to perform a pilot study at the Manitoba Men's Health Clinic to assess if pre-vasectomy counseling with ChatGPT can safely streamline the consultation process by reducing visit times, while increasing patient satisfaction with the consultation process. If the hypothesis provides true, further implementation of ChatGPT in a healthcare practice may work to reduce the burden on health care providers.

There are no predicted adverse events of this study. There are no identified potential harms of this study.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing vasectomies interested in participating
* Adult (\>18 years old)
* Consenting

Exclusion Criteria:

* Do not consent, uninterested in participating
A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) or placebo in combination with rabies vaccine in healthy adult subjects.


Eligibility Criteria:
Inclusion Criteria:

* Subjects free of obvious health-problems or with stable condition
* Male or female subjects aged ≥19 to ≤65 years
* BMI between ≥18 and ≤30 kg/m2

Exclusion Criteria:

* Prior history of active or passive rabies immunization
* Clinically significant acute illness or infection within 2 weeks before first dosing based on the clinical judgment of the investigator
* History and/or family history of clinically significant immunodeficiency or auto-immune disease
* Any clinically significant history of known or suspected anaphylaxis or hypersensitivity reaction
* Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational medicinal product
Adapted Physical Activity Education in Patients With Neurocognitive Disorder

This study aims to compare the effect of a program of Adapted Physical Activity (APA) versus the same program combined with a physical activity education program (PAE). Patients suffering from neurocognitive disorders (mild or early major) will be randomized into one of the two conditions. 3 complete evaluations will be done (inclusion M0, after 3 month of intervention M3, 3 months after the end of the intervention M6). The team except that APA+PEA will be more effectiv than the APA solely, on the following criteria : level of physical activity, cogntive function and quality of life.


Eligibility Criteria:
Inclusion Criteria:

* mild neurocognitive disorder or early major neurocognitive disorder

Exclusion Criteria:

* Medical pathology involving the vital prognosis in the short term
* Major neurocognitive disorder at moderate stage and beyond (DSM 5) and/or MMSE \< 20
* Unbalanced depressive syndrom
* Contraindication to the practice of the exercises proposed during the study;
* Major hearing or visual impairment;
* Sufficiently active with regard to the daily recommendations described by the WHO
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose escalation and safety expansion which determines the optimal dose and maximum number of tolerated doses. Part 2 is dose expansion in which Part 1 recommended dose will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
* Part 1: Participants with advanced or metastatic solid tumors.
* Part 2: Participants with advanced or metastatic adenocarcinoma of endometrium, melanoma, non-small cell lung cancer, and renal cell carcinoma.
* Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or participants who refuse standard treatment.
* Presence of measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

Exclusion Criteria:

* Laboratory and medical history parameters not within the protocol-defined range.
* Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
* Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy.
* Receipt of a live vaccine within 30 days of planned start of study therapy.
* Active autoimmune disease.
* Prior treatment with any tumor necrosis factor super family agonist.
* Known active central nervous system metastases and/or carcinomatous meningitis.
* Evidence of active, non-infectious pneumonitis or history of interstitial lung disease.
* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion

The changes of ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion by ultra-wide field fluorescence angiography (UWFA)

In this study, the ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion will be evaluated by ultra-wide field fluorescence angiography (UWFA). UWFA has a wider range than conventional angiography, and can clearly observe the peripheral retina. The purpose of this study is to quantitatively analyze these changes and investigate the effect on macular edema and neovascularization secondary to retinal vein occlusion.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female aged 18 years or more
2. Patients with a diagnosis of CRVO,BRVO or HRVO without macular edema
3. Duration of RVO not more than 4 months
4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) which completely resolved (normalization of visual acuity and fundus examination) and who experienced a recurrence of RVO are also considered naive
5. Patient who agrees to participate to the study and who has given his/her written, informed consent

Exclusion Criteria:

1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
2. Active or suspected ocular or periocular infection
3. Active severe intraocular inflammation
4. RVO complicated with neovascularization
5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye
6. Patient already included in the study for the treatment of the fellow eye
7. Pregnant or breastfeeding woman
8. Lack of effective contraception for women of childbearing age
9. Patient taking part in an interventional study
Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries

The purpose of this study is to determine if intrathecal hydromorphone will relieve pain as well as intrathecal morphine after cesarean delivery, with fewer side effects.

Intrathecal morphine has long been the standard pain medication used in cesarean sections. Since some patients cannot tolerate morphine, hydromorphone may be an acceptable alternative. Intrathecal Intrathecal hydromorphone has been shown to be effective at treating post cesarean section pain and possibly with less side effects than morphine.

One side effect of morphine is respiratory depression occurring hours after the start of morphine use. Respiratory depression occurs when air being taken into the lungs is less than normal, leading to a lower amount of oxygen and carbon dioxide being exchanged in the blood stream. Because hydromorphone dosages are lower and it has a quicker onset of action than morphine, it is believed that the use of hydromorphone should decrease the possibility of delayed respiratory depression.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled for elective Cesarean sections under spinal anesthesia or combined spinal anesthesia
* ASA status of I-III
* BMI \< 40
* Able to understand and sign informed consent

Exclusion Criteria:

* Severe pre-eclampsia
* Conversion to general anesthetic
* History of chronic opioid use
* Allergy to morphine, or hydromorphone
* Hyperemesis gravidarum
* Emergency case
* Patients who have an infection at the intended site of spinal insertion